Blue Jet Healthcare Ltd

- The company currently remains debt-free with robust internal accruals supporting its expansion plans (Page 4). - No specific mention of new fundraising through debt or equity in the discussed transcript. - Expansion, including the Mahad backward integration facility and Vizag site development (Phase-I CAPEX approx. Rs. 1,000 crores), appears to be funded internally through accruals. - The focus remains on capital discipline while scaling up capacity and innovation (Page 4). - Overall, no announced plans or indications of raising funds via new debt or equity rounds as of the quarter ended September 30, 2025.

- Blue Jet Healthcare is expanding capacity with a major CAPEX plan including a new 103-acre site in Vizag. - Phase-I of Vizag project, with an approximate CAPEX of Rs. 1,000 crores, will have 4 blocks: 2 for Contrast Media, 1 for high-intensity Sweetener, and 1 multipurpose block including peptide fragments for GLPs; expected completion by FY '28. - Backward integration facility at Mahad with a CAPEX of about Rs. 300 crores (increased from Rs. 250 crores due to automation); commissioning expected by H2 FY '26. - A state-of-the-art R&D center is planned in Hyderabad at a cost of Rs. 40 crores to enhance capabilities including peptides, GLP1 intermediates, and biocatalysts. - Over the next 2-3 years, the company plans to add another 1,000 KL capacity to keep pace with client requirements. - Total capital investment supports strategic independence, supply chain resilience, and growth in chronic disease and innovator-focused molecules.

- The company anticipates stable to growing order book momentum with strong medium to long-term visibility fueled by global customer commitments. - Capacity expansions at Vizag (103 acres) and backward integration facility at Mahad are on track, with Phase-I at Vizag targeting completion by FY '28, adding 1,000 KL capacity over 2-3 years. - Growth in the cardiovascular drug segment (notably Bempedoic Acid) is expected to continue, with triple-digit percentage growth reported and approvals in new markets like Japan expanding opportunities. - Contrast media shipments faced transit delays but volumes and revenues are expected to normalize and sustain at FY '23 levels over the next 12-18 months. - Pharma intermediate and API revenues showed strong H1 growth, with new product launches and capacity enhancements poised to support scaling. - Overall, growth drivers include multiple late-stage NCE/R&D projects, new market entries, and stable gross margins with gradually improving margin profiles due to backward integration and resilience building.

- The company expects stable to improving revenues in the contrast media segment over the next 12-18 months, driven by commercial-scale launch of new iodinated intermediates and growth in the NCE molecule for MRI. - The Pharma Intermediates and API segment is poised for good growth, especially with expansion in chronic disease molecules and triple combination therapies. - Backward integration at Mahad is expected to improve business continuity and margins gradually over the next few quarters. - Capacity expansions, including a Rs. 1,000 crore Phase-I development at Vizag, will add 1,000 KL capacity by FY '28, supporting medium-term growth aspirations. - EBITDA margins have remained healthy at 36% in Q2 FY '26, with expectations of more stable gross margins going forward due to reduced volatility in transit-related issues. - The company is focused on disciplined execution and capacity-led growth to sustain quality earnings and margin expansion over the medium to long term.

- The order book visibility for contrast media (marketed product) remains stable as per management comments. - The order book for intermediates, specifically for the NCE molecule, is noted to be encouraging. - Commercial scale supply for iodinated intermediates expected to commence in Q4 of the financial year. - Management emphasized a long-term view on capacity build-up aligned with orders, indicating visibility over 5 years, though ramp-up timing may vary by 12-18 months. - Customer off-take and schedules cause some quarter-on-quarter volatility but overall order book remains solid. - Growth prospects for Pharma Intermediate segment, including Bempedoic Acid and other chronic disease molecules, supported by good order visibility and new approvals. - Strong long-term contracts in place protecting capacity utilization and opportunity in key molecules like Bempedoic Acid. - Transit and channel inventory destocking caused short-term fluctuations but normalized over the medium term, supporting steady order execution.